CDNA:NSD-Caredx Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 18.9

Change

0.00 (0.00)%

Market Cap

USD 1.25B

Volume

0.88M

Analyst Target

USD 44.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-16 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

N/A

USD 35.55B
NTRA Natera Inc

N/A

USD 21.03B
ICLR ICON PLC

N/A

USD 16.66B
ILMN Illumina Inc

N/A

USD 14.06B
MEDP Medpace Holdings Inc

N/A

USD 9.97B
EXAS EXACT Sciences Corporation

N/A

USD 9.13B
GH Guardant Health Inc

N/A

USD 4.85B
RDNT RadNet Inc

N/A

USD 4.54B
SHC Sotera Health Co

N/A

USD 3.23B
VCYT Veracyte Inc

N/A

USD 3.18B

ETFs Containing CDNA

ARCG:LSE ARK Genomic Revolution UC.. 4.49 % 0.00 %

N/A

USD 9.51M
ARKG:LSE ARK Genomic Revolution UC.. 4.41 % 0.00 %

N/A

USD 9.33M
ARKG ARK Genomic Revolution ET.. 4.19 % 0.75 %

N/A

USD 1.06B
JFWD 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.72% 57% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.72% 57% F 37% F
Trailing 12 Months  
Capital Gain 86.39% 87% B+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 86.39% 87% B+ 94% A
Trailing 5 Years  
Capital Gain 25.25% 66% D+ 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.25% 66% D+ 44% F
Average Annual (5 Year Horizon)  
Capital Gain 25.20% 69% C- 78% C+
Dividend Return 25.20% 69% C- 77% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 115.33% 31% F 19% F
Risk Adjusted Return 21.85% 73% C 55% F
Market Capitalization 1.25B 67% D+ 75% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector